Poster Abstracts • OFID 2018:5 (Suppl 1) • S91 [OR 0.88, (0.84, 0.88), P < 0.001]. Bronchitis/URI-NOS prescribing rates decreased from 2009 [annual OR 0.94 (CI 0.93, 0.95), P < 0.001]. Additional effect was observed postintervention [OR 0.86, (0.81, 0.91), P < 0.001]. Overall, the proportion of ARI visits diagnosed with sinusitis increased [annual OR 1.09 (1.08, 1.10), P < 0.01], but the proportion of sinusitis diagnoses decreased [OR 0.72 (0.69, 0.75), P < 0.001] postintervention. Guideline-concordant antibiotic selection was 61.5% vs. 71.2% for sinusitis and 63.3% vs. 67.8% for pharyngitis pre-/postintervention, respectively (both P < 0.001).
Background. Antimicrobial stewardship programs (ASPs) reduce the burden of multidrug-resistant organisms and improve antibiotic prescribing. Concerns about drug-resistant pathogens (DRPs) in community-acquired pneumonia (CAP) lead to over-prescribing of broad-spectrum antibiotics, and ASP interventions to improve CAP prescribing are not well defined. In 2017, our hospital implemented a CAP guideline for patients at low risk for DRPs along with ASP support. The purpose of this study was to evaluate the impact of the guideline with ASP support on CAP-specific antibiotic prescribing.
Methods. This was a pragmatic two-phase quasi-experimental analysis of CAPspecific antibiotic consumption before and after implementation of a CAP guideline evaluated according to each phase of implementation. The guideline provided Grampositive and Gram-negative risk factors and guidance on oral fluoroquinolone (FQs) alternatives. ASP interventions were implemented in two phases: (A) prospective audit and feedback in July 2016 and (B) publication of guideline with education in March 2017. Impact of each intervention was evaluated by interrupted time series segmented-regression analysis. Univariate statistics were calculated using EpiInfo 7. Leastsquares segmented regressions were completed in Microsoft Excel.
Results. CAP-specific antibiotic administrations were 782 over the entire study period, with 764, 771, and 928 administrations observed before phase A, after A, and after B, respectively. Macrolide consumption increased after the guideline (P = 0.029). We observed a significant step change decrease in FQ consumption was observed after phase A) (P = 0.039) and a positive upward trend in oral alternatives agents after phase B (P = 0.090), as shown in the figure. Consumption of broad Gram-negative agents and vancomycin/linezolid were not significantly different after the guideline.
Conclusion. Implementation of a CAP guideline with patient-specific and DRP risk factors was associated with significant changes in CAP-specific prescribing. Changes in prescribing were temporally associated with ASP interventions. Additional studies into the impact of this guideline on correct classification of Gram-negative resistance and clinical outcomes are needed. Thursday, October 4, 2018: 12:30 PM Background. Due to poor sensitivity, the FDA mandated that rapid influenza antigen (IAT) must be phased out by 2018. At our institution an on-site rapid influenza PCR (PCR) was implemented in emergency departments (ED) at the start of the 2016-2017 influenza season. The purpose of this study was to examine the impact of influenza PCR testing on antimicrobial utilization in the ED.
Improved Antimicrobial Utilization in the Emergency
Methods. This multicenter quasiexperimental study included adults over the age of 50 who were tested for influenza, and discharged from the ED. Subjects were matched 2:1 by age, sex, month of testing, and ED site. The pre-implementation group had IAT (January-April 2016) and the post-implementation had PCR testing (JanuaryApril 2017). The primary outcome was antiviral utilization. Other outcomes included diagnostic yield, test turnaround time (TAT), receipt of antibiotics, and 30-day revisit.
